Encepheal Therapeutics YC-Bewerbung

Summer 2019Inactive

Encepheal Therapeutics durchlief Y Combinator im Summer 2019-Batch als ein Healthcare-Unternehmen. Unten: Was das Unternehmen tut, wer es gegründet hat und seine Bewerbung bei YC, Frage für Frage im echten YC-Formular rekonstruiert.

YC-Batch: Summer 2019
Branche: HealthcareTherapeutics
Teamgröße: 3
Status: Inactive
Gestartet: 2019

Gründer

Aaron LazarusFounder
Omeed RahimiFounder

Was Encepheal Therapeutics tut

EncepHeal is developing medications to treat substance abuse. Our first product is a small molecule therapeutic for stimulants like cocaine and methamphetamine, of which there are no FDA approved treatments. Our small molecule technology are atypical inhibitors of the dopamine transporter. Cocaine itself is an inhibitor of the same transporter. Directly reducing craving or positive reinforcement is a successful treatment strategy for addiction. Methadone or buprenorphine (Suboxone) are key examples of this for opioid use disorder. However, these types of medications can be addictive themselves. This has been a major hurdle for medication development for cocaine addiction and has led to many leaders in the addiction space to abandon the dopamine transporter as a target. At EncepHeal, we believe that the dopamine transporter should not be abandoned and instead focusing on fixing the abuse liability problem. Therefore with our partners at the National Institutes of Health, we have shown that these new, allosteric modulators at the dopamine transporter do not display addictive tendencies in animal models. They are also effective at curbing cocaine addiction. Our management team has two co-founders, Omeed Rahimi and Aaron Lazarus, as well as an experienced addiction pharmacologist as their research officer. The team has an advisory board with entrepreneurial and addiction drug development experience as well as expert partners at the National Institute on Drug Abuse, a subset of the NIH, and Wake Forest. Our team has had success in raising non-dilutive funding and has expertise with SBIR/STTR grants. We are looking for help in better connecting with the biotech/pharmaceutical industry.

Encepheal Therapeuticss YC-Bewerbung, rekonstruiert

Y Combinator Bewerbung

Encepheal Therapeutics, Summer 2019 Batch. Die echten Fragen des Antrags, beantwortet aus öffentlichen Daten.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Encepheal Therapeutics

Describe what your company does in 50 characters or less.

Medications to treat substance abuse

What is your company going to make? Please describe your product and what it does or will do.

We're developing small molecule drugs that target the dopamine transporter to treat stimulant addiction, starting with cocaine and methamphetamine. Our compounds modulate the dopamine transporter allosterically to reduce addictive cravings without the addictive properties of current dopamine transporter inhibitors.

Where do you live now, and where would the company be based after YC?

We currently live and work in Winston-Salem, NC, and the company is based there. After YC, we plan to maintain our base in Winston-Salem due to our partnerships and existing infrastructure.

Explain your decision regarding location.

We chose Winston-Salem because we have strong research collaborations with the National Institutes of Health and Wake Forest, which are local. This proximity helps us advance our drug development efficiently.

21 weitere Antworten in der vollständigen Bewerbung

Founders, Progress, Idea, Equity, Curious, Batch Preference sind in der Vollversion. Erstelle ein kostenloses Konto, um es in YC Insights neben jedem anderen YC-Batch zu öffnen.

Vollständige Bewerbung anzeigen

Häufig gestellte Fragen

Ist das die echte YC-Bewerbung von Encepheal Therapeutics?

Nein. Y Combinator hält eingereichte Bewerbungen privat. Dies ist eine Rekonstruktion: die echten Fragen des YC-Formulars, beantwortet aus den öffentlichen Daten von Encepheal Therapeutics (Veröffentlichungsnotizen, Gründerhintergründe, Produktbeschreibung). Sie zeigt, wie sich ein Unternehmen wie Encepheal Therapeutics bei YC präsentieren würde, nicht den Text, den sie eingereicht haben.

In welchem YC-Batch war Encepheal Therapeutics?

Encepheal Therapeutics war Teil des Y Combinator Summer 2019-Batches.

Wer hat Encepheal Therapeutics gegründet?

Encepheal Therapeutics wurde von Aaron Lazarus, Omeed Rahimi gegründet.

Was macht Encepheal Therapeutics?

EncepHeal develops medications to treat substance abuse, starting…

Wie lese ich die vollständige, rekonstruierte Bewerbung?

Erstelle ein kostenloses Round Funded Konto. Die vollständige 26-Antwort-Version der Bewerbung von Encepheal Therapeutics, und jede andere YC-Kohorte, findest du in YC Insights.